CELG/Revlimid CALGB trial in treating patients who are undergoing autologous stem cell transplant for multiple myeloma was stopped early due to superior efficacy:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.